Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2018-01-02
Target enrollment:
Participant gender:
Summary
This open-label study is designed to obtain preliminary data on the efficacy of a new depot
formulation of goserelin, Pepti 10.8mg, in ambulatory patients with carcinoma of the prostate
who, in the opinion of the Investigator, is a candidate for androgen deprivation therapy,
after a single injection. Secondarily, it is designed to assess the pharmacokinetics, safety
profile and PSA response of this new formulation.